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Abstract 
 
Aims 
Clinical and observational studies have demonstrated increased risk of cardiovascular events and death 
associated with sulfonylureas versus metformin. However, it has never been determined whether this 
was due to the beneficial effects of metformin or detrimental effects of sulfonylureas. Our objective was 
therefore to compare all-cause mortality in diabetic patients treated first-line, glucose lowering therapy 
with either sulfonylurea or metformin monotherapy with that in matched individuals without diabetes. 
Materials and Methods 
We used retrospective observational data from the UK Clinical Practice Research Datalink (CPRD) from 
2000. Subjects with type 2 diabetes who progressed to first-line treatment with metformin or 
sulfonylurea monotherapy were selected and matched to people without diabetes. Progression to all-
cause mortality was compared using parametric survival models that included a range of relevant co-
variables. 
Results 
We identified 78,241 subjects treated with metformin, 12,222 treated with sulfonylurea, and matched 
90,463 cases without diabetes. This resulted in a total, censored follow-up period of 503,384 years. 
There were 7,498 deaths in total, representing unadjusted mortality rates of 14.4 and 15.2, and 50.9 and 
28.7 deaths per 1,000 person-years for metformin monotherapy and their matched controls, and 
sulfonylurea monotherapy and their matched controls, respectively. With reference to observed survival 
in diabetic patients initiated with metformin monotherapy, adjusted median survival time was 15% 
lower (survival time ratio=0.85, 95%CI 0.81–0.90) than in matched individuals without diabetes, and 
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adjusted median survival time was reduced by 38% (survival time ratio=0.62, 0.58–0.66) in diabetic 
patients treated with sulfonylurea monotherapy.  
Conclusions 
Patients with type 2 diabetes initiated with metformin monotherapy had longer survival than did 
matched, non-diabetic controls. Those treated with sulfonylurea had markedly reduced survival than 
both matched controls and those receiving metformin monotherapy. This supports the position of 
metformin as first-line therapy and implies that metformin may confer benefit in non-diabetes. 
Sulfonylurea remains a continued concern.   
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Introduction 
Type 2 diabetes is a condition that affects 8% of the US population1 and 4% of the UK population.2 Good 
glucose control is important to reduce the risk of developing microvascular complications. This is initially 
achieved through diet and exercise, but glucose-lowering medication is required in most patients with 
progressing diabetes. Metformin is recommended as the first-line therapy for type 2 diabetes in the 
current ADA/EASD guidelines.3  
In the UK, the proportion of people with type 2 diabetes treated with sulfonylureas decreased from 45% 
in 1996 to 33% in 20054, and the number of people using metformin increased from 30% to 57% over the 
same period.5 In the USA, the percentage of patients initially treated with sulfonylureas decreased from 
61% in 1997 to 22% in 2012, while the proportion of patients initiating therapy with metformin increased 
from 23% in 1997 to 53% in 2012.6 However, sulfonylureas are still commonly prescribed, especially 
when metformin is contraindicated, and it is relatively common to use sulfonylurea subsequent to 
metformin monotherapy.7 By far the most common second-line glucose-lowering therapy is a 
combination of metformin and sulfonylurea7, although metformin was not approved by the FDA until 
1995.8  
Unlike metformin, sulfonylureas can cause weight gain and hypoglycemia, thought to have a detrimental 
impact on cardiovascular risk.9,10,11,12 In addition, it has been hypothesized that sulfonylureas may cause 
cardiovascular side-effects by inhibiting KATP channels in cardiac muscle, thereby blocking ischemic 
preconditioning (a cardioprotective mechanism).13,14 On the other hand, metformin has been associated 
with beneficial effects, which include a cardioprotective effect that cannot be solely explained by its 
antihyperglycemic effect.15,16,17 Furthermore, metformin is believed to have anti-cancer properties, 
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which would also impact on mortality risk.18,19 A discussion of the relative merits of these two glucose 
lowering drugs was published recently in Diabetes, Obesity and Metabolism.4  
Demonstration of the efficacy and safety of glucose-lowering drugs with regard to hard clinical 
endpoints―especially cardiovascular outcomes―is important and now a regulatory requirement for 
new glucose-lowering medicines. This is no less important for long-established treatments. In the 
absence of adequately powered prospective trials, retrospective data are essential to help address 
continuing uncertainty. 
Previous clinical and observational studies comparing metformin and sulfonylureas have demonstrated 
an increased risk of cardiovascular events and death associated with the use of sulfonylureas compared 
with metformin.20,21 However, it is difficult to determine whether this is due to the beneficial effects of 
metformin or to detrimental effects associated with sulfonylureas.  
The primary aim of this study was to compare the risk of all-cause mortality associated with first-line 
sulfonylurea monotherapy or first-line metformin monotherapy with that of matched non-diabetic 
controls.  
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Materials and Methods 
Data source 
The data source was the Clinical Practice Research Datalink (CPRD).22 CPRD contains clinically rich, 
pseudonymized data collected from primary-care physicians in the UK. The following data were 
available: demographics; symptoms and diagnoses; prescriptions; immunizations; results of 
investigations; referrals to specialists and secondary care; feedback from other care settings; and 
lifestyle information such as body mass index (BMI), smoking,  and exercise. CPRD is broadly 
representative23 and contains data from over 13 million research-quality patients. Details of hospital 
admissions are also provided for the majority of patients. Data were available to July 2013. Approval for 
this study was granted by the CPRD Independent Scientific Advisory Committee (reference 12_151RAR).  
 
Patient selection 
Patients classed by CPRD as being of acceptable research quality were selected if diagnosed with type 2 
diabetes and exposed to glucose-lowering therapy. Patients were excluded if they had any record of 
secondary diabetes.  
Patients were defined as incident diabetes cases based on a wash-in period of at least 180 days from 
registration to diagnosis. Patients subsequently initiated with sulfonylurea or metformin from 2000 were 
selected, providing they received treatment for a minimum of 180 days. The index date was defined as 
that of the first sulfonylurea or metformin prescription. Patients were followed to death or censorship.  
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Cases were matched to people without diabetes using the following criteria: age at baseline (±2 years), 
gender, same general practice, prior cancer status, and smoking status. The index date for the controls 
was the same as that of their corresponding case. Only individuals with ≥180 days’ survival following 
index date were included as controls. 
 
Study endpoint 
The study endpoint was all-cause mortality. For diabetic patients who died, the event date was defined 
as the patient’s date of death provided that this occurred before the censor date, defined as the earliest 
of a) the end of the recorded data, b) 90 days from regimen change, or c) five years plus 180 days from 
the index date.  
For controls that died, the event date was defined as the patient’s recorded date of death provided that 
this was prior to the end of the recorded data, the censor date for the corresponding case, or the 5½ 
year follow-up period. Otherwise cases were censored. The censor date here was defined as the earliest 
of the end of a patient’s recorded data, the censor date of their corresponding case, or the end of the 5½ 
year follow-up period. 
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Statistical methods 
Continuous baseline characteristics were compared using the independent t-test or Mann-Whitney U 
test depending on their distribution. Categorical variables were compared using the chi2 test. Differences 
in survival in Kaplan–Meier (KM) analysis were compared using the log-rank test. 
Candidate covariates for modeling survival comprised age, Charlson comorbidity index, 24 gender, 
smoking status, prior anti-platelet therapy, prior lipid-lowering therapy, prior anti-hypertensive therapy, 
index year, and study arm. Glycated hemoglobin (HbA1c), systolic blood pressure, total cholesterol, 
creatinine, and BMI were not considered because their large proportions of missing data in controls.Prior 
major adverse cardiac events (MACE) are components of the Charlson index. All categorical variables 
were treated as discrete and converted to binary variables with the exception of index year and Charlson 
index. 
People with type 2 diabetes have a minimum Charlson index of one or two units, depending on whether 
they did or did not have complications, respectively. Here, group status indicated diabetes status. The 
Charlson index was modified to subtract one unit from all patients with diabetes so that uncomplicated 
diabetes contributed nothing to the index, and diabetes with complications contributed one unit. Other 
comorbidities contributed to the index conventionally.  
Continuous variables (age and modified Charlson) were modeled using restricted cubic splines to allow 
for non-linear effects. The start date for the survival analysis was defined as the index date +180 days’ 
treatment exposure. The survival analysis was truncated at 5½ years as the average duration of first-line 
monotherapy was three years.  
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Modeling of survival was not performed with a Cox proportional hazards model because the 
proportional hazards assumption was violated. We therefore fitted a parametric accelerated failure time 
(AFT) survival model. Weibull, log-normal, and log-logistic models were assessed for goodness of fit using 
the Akaike information criterion (AIC).25 The log-logistic model resulted in the best fit in terms of AIC, and 
the adequacy of this distribution was further assessed by plotting appropriately transformed 
nonparametric estimates against time. The log-logistic survival model provides beta coefficients that 
equal the difference in log survival time between groups or for continuous predictors. Exponentiation of 
the beta coefficient gives the ratio between median survival times, known as the survival time ratio 
(STR), or acceleration factor. STRs less than one represent a decrease in survival time; values greater 
than one represent prolonged survival. 
All candidate covariates were included in the final model with no variable selection performed, since it 
has been shown that excluding statistically insignificant variables does not improve predictive accuracy 
and makes accurate confidence intervals hard to obtain.26 
Extensive sub-group analyses are reported using the final model.  To enable the impact of concomitant 
cardioprotective medications to be evaluated over time, three variants of the final model were 
developed: model variants 1–3 replaced baseline values for antihypertensive, lipid-lowering, and 
antiplatelet therapy with values for the first one, two, or three years of study, respectively.  Patients 
were excluded if they were censored within the relevant years and had received a different combination 
of antihypertensive, antiplatelet, and lipid-lowering therapy in those years. All statistical analyses were 
performed using R software.27  
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Results 
78,241 subjects treated with metformin and 12,222 treated with sulfonylurea were identified. 78,241 
and 12,222 non-diabetic patients were matched to their respective cases. Subjects were followed from 
their index date for an average of 2.8 (median 2.4) years, representing a censored total follow-up period 
of 503,384 years.  
 
Baseline characteristics 
Metformin monotherapy compared with sulfonylurea monotherapy 
Patients in the sulfonylurea group were older than those treated with metformin (mean age of 67.8 
versus 61.2, respectively; p<0.001). Patients in the sulfonylurea group had higher baseline HbA1c values 
(9.2 vs 8.6%; p<0.001) and serum creatinine (97.9 vs 84.2 µmol/l; p<0.001). Baseline, unmodified 
Charlson index was higher in the sulfonylurea group than in the metformin group (2.3 versus 1.9; 
p<0.001). There was also a higher percentage of people who had previously had cancer (14% versus 10%; 
p<0.001) and/or MACE (16% versus 10%; p<0.001) in the sulfonylurea group. Conversely, a higher 
percentage of people in the metformin group had previously been prescribed lipid-lowering therapy 
(50% versus 35%; p<0.001). Baseline characteristics are detailed in Table 1. 
Relative morbidity between these two groups at baseline was difficult to gauge because of differing 
mean age.  
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Metformin monotherapy compared with matched control group 
BMI was highest for those treated with metformin (32.4 kg/m2 versus 27.4 kg/m2; p<0.001) (Table 1), 
and people in the metformin group also had more GP consultations in the year prior to treatment 
initiation (11.3 versus 6; p<0.001). In addition, people in the metformin group were more likely to have 
had a previous MACE (10% versus 6%; p<0.001) and to have previously received prescriptions for lipid-
lowering (50% versus 20%; p<0.001), antihypertensive (66% versus 39%; p<0.001), and/or anti-platelet 
medications (36% versus 19%; p<0.001) (Figure 1). Non-diabetic controls had less morbidity than cases. 
 
Sulfonylurea monotherapy compared with matched control group 
The Charlson index was higher for patients in the sulfonylurea group than for those in the control group 
(2.3 versus 0.8; p<0.001) as was the number of GP contacts in the year prior to index date (11.7 versus 
6.5; p<0.001) (Table 1). In addition, people in the sulfonylurea group were more likely to have had a 
MACE (16% versus 9%; p<0.001) and to have previously received prescriptions for lipid-lowering (35% 
versus 17%; p<0.001), antihypertensive (64% versus 45%; p<0.001), and/or anti-platelet therapies (38% 
versus 25%; p<0.001) (Figure 1). Controls had far less morbidity than cases. 
 
Numbers of deaths and crude event rates 
In total there were 7,498 deaths, corresponding to an unadjusted event rate of 18.1 deaths per 1,000 
person-years. Unadjusted event rates were highest in the sulfonylurea group and lowest in the 
metformin group (50.9 vs 14.1 per 1,000 person-years respectively; p<0.001) (Table 2). Similarly, 
unadjusted event rates were higher in sulfonylurea-treated patients compared with matched controls 
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(50.9 vs 28.7 per 1,000 person-years, respectively; p<0.001) but surprisingly were lower in those treated 
with metformin compared with matched controls (14.1 vs 15.2 per 1,000 person-years respectively; 
p=0.054). Unadjusted event rates were lowest in people aged <60 years at index date and highest for 
people aged >70 years for both diabetic and control subjects. 
 
Unadjusted survival patterns 
KM survival curves, stratified by treatment arm and diabetes status are illustrated in Figure 2. Favoring 
metformin, these survival curves show that overall there was little discernible difference between 
metformin cases and non-diabetic controls (p=0.037; Figure 2a). This was not the case in those treated 
with sulfonylureas vs controls, where those treated with sulfonylureas had markedly reduced survival 
(p<0.001; Figure 2b). KM curves are also presented for patients aged 71–75 years: the most frequent age 
group for incident sulfonylurea initiation (Figure 2c). Reassuringly, the two groups of non-diabetic 
controls resulted in the same pattern of survival (p=0.879); however, there was improved survival in 
people exposed to metformin vs controls (p<0.001) and reduced survival in the sulfonylurea group vs 
controls (p<0.001).   
 
Adjusted survival patterns 
With reference to the observed survival in the group initiated with metformin, the median survival time 
was 15% lower in controls (STR=0.85; 95% CI 0.81–0.90) and 38% lower (0.62; 0.58–0.66) in patients with 
type 2 diabetes treated with sulfonylurea (Figure 3: final model).  
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These patterns remained generally consistent across a wide range of clinically relevant sub-groups 
(Figure 3). The central points of the STRs did not cross unity in a discordant way in analysis of any 
subgroup. However, a number of interesting patterns emerged. When compared with matched, non-
diabetic controls, diabetic patients with high co-morbidity who were treated with metformin had 
particularly improved survival (Charlson ≥3; STR=0.67; 0.59—0.77), and this pattern increased with 
increasing morbidity (Figure 3). Importantly, survival was better with metformin even in those people 
who had not received cardiac prophylactic medications at baseline, but consistent survival benefits were 
seen with metformin when used in people with a prior history of each prophylactic treatment sub-group.  
With regard to decreased survival in subjects with diabetes treated with sulfonylurea compared with 
metformin, those initiated at a younger age were at a particularly increased relative risk (≤53 years: 
STR=0.34; 95% CI 0.22–0.53). Furthermore, the difference appeared to increase over calendar time: the 
STR was 0.62 (0.56–0.68) in those initiating treatment between 2000 and 2004, and 0.46 (0.33–0.64) in 
those initiating between 2011 and 2012 (Figure 3). Adjustment for up to three years’ continuous 
exposure to concomitant cardioprotective prophylaxis had no notable impact on relative STRs for 
metformin and sulfonylureas (Figure 3: model variants 1–3).   
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Discussion 
We have shown that in a contemporary UK population, use of metformin for first-line, glucose lowering 
treatment was associated with survival that was at least as good as that of matched, non-diabetic 
controls. Treatment with first-line sulfonylurea monotherapy was associated with increased mortality.  
There remains considerable conjecture about the relative merits of metformin versus sulfonylureas.4 
Reported differences in safety generally favour metformin. If one accepts that there exists a difference in 
outcome between these two glucose-lowering medications favouring metformin, it has not yet been 
established whether this is due to the beneficial impact of metformin or a detrimental impact of 
sulfonylureas. Here we uniquely introduced non-diabetic controls into an evaluation of these 
treatments, and the findings were illuminating. Patients treated with metformin had a small but 
statistically significant improvement in survival compared with matched, non-diabetic controls, whereas 
those treated with sulfonylureas had consistently reduced survival versus non-diabetic controls. There 
also remained a difference in outcome between those taking metformin and sulfonylurea, although this 
needs to be interpreted with caution because we did not adjust for important covariates because they 
were unavailable in the non-diabetic subjects. This was carried out in separate but related studies in this 
journal, and showed worse outcome with metformin.7,12,28 Importantly, these data not only demonstrate 
once again a better outcome with metformin relatively to sulfonylurea but suggest that this is due to a 
beneficial effect of metformin on all-cause mortality.  
Surprisingly, patients treated with metformin had a slightly longer adjusted survival than matched, non-
diabetic controls, despite greater morbidity. This was independent of cardiovascular disease prophylaxis.      
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Evidence in support of the use of metformin as first-line, glucose-lowering therapy originated largely 
from the UKPDS, where obese patients receiving metformin had lower incidence of diabetes-related 
endpoints, including all-cause mortality when compared with intensive treatment with sulfonylureas or 
insulin.29 A relative benefit of metformin has also been reported in various observational 
studies.30,31,32,33,34,35,36,37 Mixed results were observed, however, in meta-analyses with metformin versus 
comparators or placebo. A significant cardiovascular benefit was observed in trials comparing metformin 
versus placebo/no therapy (odds ratio 0.79; p=0.031) but not in active-comparator trials (odds ratio 1.03; 
p=0.89).38 Meta-analysis of currently available RCT data does not support the hypothesis that metformin 
lowers cancer risk by one-third. Eligible trials also showed no significant effect of metformin on all-cause 
mortality. However, limitations include heterogeneity, absent cancer data from two trials, and short 
follow-up, especially for mortality.39 This included increased risk of cancer in both observational 
studies40,41,42 and meta-analyses.43,44  
 
Study limitations 
Our study included a large number of patients followed up for a median of 2.4 years. Unlike RCTs, less 
strict inclusion and exclusion criteria are often used in observational studies. The data source used for 
this study, CPRD, contained data collected from routine practice, therefore some data may be missing 
and coding imperfections may lead to diabetes misclassification. However, only those patient records 
meeting CPRD’s quality criteria were included, and rules were applied to maintain consistency in the 
selection of patients with type 2 diabetes. Data quality in CPRD is considered to be good.45 
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As this was an observational study, patients were not randomized to treatment, and uncharacterized 
confounders may account for some of the differences between groups. Although differences in baseline 
characteristics existed between the four groups, these were adjusted for as far as possible in the models. 
However, we could not adjust for some parameters due to the understandably high percentage of 
missing data in controls. This may impact on the comparison between metformin monotherapy and 
sulfonylurea monotherapy particularly. We did not investigate for a dose response association in this 
study, however, this would be interesting. We have detailed the profile of the specific types of 
sulfonylureas that are commonly used in these cohorts in another study, and this is 90% gliclazide.28  
Symptoms of type 2 diabetes can be mild and people with type 2 diabetes can remain undiagnosed for 
many years.46 Therefore, it is likely that some controls had undiagnosed type 2 diabetes. 
Due to the association between type 2 diabetes and increased cardiovascular risk, people with type 2 
diabetes are likely to be receiving exercise and lifestyle interventions and close monitoring and control of 
blood pressure and cholesterol levels. Hypertension and hypercholesterolemia are risk factors for 
cardiovascular disease but are generally asymptomatic. Therefore, these conditions may be less well 
diagnosed in the control group.  
 
Conclusion 
Considered as a whole, our data suggest that patients with diabetes treated with metformin 
monotherapy can expect their survival to be at least as good as that of the non-diabetic population 
whilst on this specific regimen. We remain unsure about how relative survival changes relative to those 
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without diabetes once glucose-lowering treatment is intensified, although metformin plus sulfonylurea 
combination therapy remains concerning7,28. Here, this was not the case for people treated with 
sulfonylurea monotherapy, where our findings further support the hypothesis that this drug class 
increases the risk of all-cause mortality. Intriguingly, these findings suggest that there may be a 
prognostic benefit of metformin prophylaxis in people without diabetes.  
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Figure 1 | Use of cardiovascular prophylactic medications during the study follow-up 
a) Antihypertensives 
 
 Metformin monotherapy  Controls (matched with metformin) 
 Sulfonylurea monotherapy  Controls (matched with sulfonylurea)  
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b) ACE inhibitors/Angiotensin II antagonists 
 
 Metformin monotherapy  Controls (matched with metformin) 
 Sulfonylurea monotherapy  Controls (matched with sulfonylurea)   
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c) Statins 
 
 Metformin monotherapy  Controls (matched with metformin) 
 Sulfonylurea monotherapy  Controls (matched with sulfonylurea)  
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d) Antiplatelets 
 
 Metformin monotherapy  Controls (matched with metformin) 
 Sulfonylurea monotherapy  Controls (matched with sulfonylurea)  
Numbers of subjects per year following index date were: 157,862 for year 1; 106,406 for year 2; 71,461 for year 3; 46,682 for year 4; 30,550, for year 5. 
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Figure 2 | Kaplan-Meier curves comparing a) metformin monotherapy with their matched 
control group without diabetes, b) sulfonylurea monotherapy with their matched control group 
without diabetes, and c) patients aged 71 to 75 years at baseline for all four cohorts (reported 
because it is the most frequent five-year interval in subjects exposed to sulfonylurea 
monotherapy) 
a) 
  
b) 
 
                                           c) 
  
 Metformin monotherapy  Controls (matched with metformin) 
 Sulfonylurea monotherapy  Controls (matched with sulfonylurea)  
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Figure 3 | Forest plot showing adjusted survival time ratios (STR), overall and for relevant diabetes-related subgroups. Data are for those initiated 
with metformin monotherapy versus non-diabetic controls (left-hand pane) and metformin monotherapy versus sulfonylurea monotherapy 
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Notes:  
Final model 1: Covariates were age, modified Charlson index, gender, smoking status, prior anti-platelet therapy (yes/no), prior lipid-
lowering therapy (yes/no), prior anti-hypertensive therapy ( yes/no), year of study index date and study arm.  
Model variant 1: Covariates were age, modified Charlson index, gender, smoking status, a score based on whether the patient had 
received antihypertensive, lipid-lowering, or antiplatelet therapy in the first year of study, year of study index date and study arm. 
Patients censored within the first year were excluded.  
Model variant 2: Covariates were age, modified Charlson index, gender, smoking status, a score based on whether the patient had 
received antihypertensive, lipid-lowering or antiplatelet therapy in the first two years of study, year of study index date and study 
arm. Patients were excluded if they were censored within the first two years and had received a different combination of 
antihypertensive, antiplatelet, and lipid-lowering therapy in those years.   
Model variant 3: Covariates were age, modified Charlson index, gender, smoking status, a score based on whether the patient had 
received antihypertensive, lipid-lowering or antiplatelet therapy in the first three years of study, year of study index date, and study 
arm. Patients were excluded if they were censored within the first three years and had received a different combination of 
antihypertensive, antiplatelet, and lipid-lowering therapy in those years.   
*The total number of patients in the complete model including patients in the control group matched with sulfonylureas (data not 
presented in this figure).  
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Table 1 | Baseline characteristics 
Parameter Metformin Sulfonylurea 
Control  
(matched with metformin) 
Control  
(matched with sulfonylurea) 
Number of people, n (%) 78,241 (43) 12,222 (7) 78,241 (43) 12,222 (7) 
Age at index, mean (SD) 61.2 (12.7) 67.8 (12.8) 61.2 (12.7) 67.8 (12.8) 
Males, n (%) 44,286 (57) 7,100 (58) 44,286 (57) 7100 (58) 
Smoking status         
Non-smoker, n(%) 36,781 (47) 6,002 (49) 36,781 (47) 6,002 (49) 
Ex- smoker, n(%) 27,662 (35) 3,879 (32) 27,662 (35) 3,879 (32) 
Current smoker, n(%) 13,798 (18) 2,341 (19) 13,798 (18) 2,341 (19) 
HbA1c, mean (SD), % 8.6 (1.8) 9.2 (2.1)     
Systolic BP, mean (SD), mmHg 138.5 (16.8) 139.7 (19.5) 136.2 (16.6) 140.7 (18.2) 
Total cholesterol, mean (SD), µmol/l 5.0 (1.2) 5.1 (1.3) 5.1 (1.1) 5.1 (1.1) 
Serum creatinine, mean (SD), µmol/l 84.2 (18.9) 97.9 (33.8) 89.1 (25.8) 95.5 (29.6) 
BMI, mean (SD), kgm2 32.4 (5.9) 27.1 (4.9) 27.4 (5.0) 26.7 (4.6) 
Charlson index*, mean (SD) 1.9 (1.3) 2.3 (1.7) 0.7 (1.2) 0.8 (1.3) 
GP contacts in the year prior, mean (SD) 11.3 (9.9) 11.7 (10.6) 6.0 (7.8) 6.5 (8.1) 
Prior cancer, n (%) 7,553 (10) 1,698 (14) 7,550 (10) 1,695 (14) 
Prior MACE, n (%) 8,162 (10) 1,995 (16) 5,058 (6) 1,119 (9) 
Prior lipid-lowering therapy, n (%) 39,407 (50) 4,303 (35) 15,913 (20) 2,112 (17) 
Prior antihypertensive therapy, n (%) 52,016 (66) 7,779 (64) 30,585 (39) 5,474 (45) 
Prior antiplatelet therapy, n (%) 28,285 (36) 4,656 (38) 14,619 (19) 3,017 (25) 
* Unmodified Charlson comorbidity index 
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Table 2 |  Crude event rate per 1,000 person-years for all-cause mortality for patients with type 2 diabetes treated with first-line 
sulfonylurea monotherapy, metformin monotherapy, or their respective matched, non-diabetic controls 
 
 Parameter Metformin Sulfonylurea Controls  (matched with metformin) 
Controls  (matched with sulfonylurea) 
Overall Number of deaths 2,663 1,418 2,669 748 
 Follow-up period (years)* 184,708 27,879 175,614 26,020 
 Crude event rate 14.4 50.9 15.2 28.7 
Age <60 years Number of deaths 249 75 223 27 
 Follow-up period (years)* 74,986 6,236 72,560 6,050 
 Crude event rate 3.3 12.0 3.1 4.5 
Age 60–70 years Number of deaths 654 235 713 125 
 Follow-up period (years)* 62,034 8,252 59,365 7,853 
 Crude event rate 10.5 28.5 12.0 15.9 
Age >70 years Number of deaths 1,760 1,108 1,733 596 
 Follow-up period (years)* 47,689 13,391 43,689 12,117 
 Crude event rate 36.9 82.7 39.7 49.2 
*Excluding the first 180 days following the index date  
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